Wed, Jul 30, 2014, 7:23 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

ViroPharma Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • ronaldo60_roothogordie ronaldo60_roothogordie Oct 26, 2012 8:48 AM Flag

    Oppenheimer upgraded VPHM from Perform to Outperform with a price target of $36.00.

    Interesting question/comment from the analyst Q&A:

    Philip Nadeau - Cowen and Company, LLC, Research Division

    Okay, great. And then just one last question, a follow up to a question that was asked earlier on capital allocation. I just wanted to ask again about stock buybacks, and I guess, the reason why I'm curious is, it doesn't seem like for the next couple of years, your stock's going to be valued on an EPS basis, it's more on top line-to-top line growth. So given the space that you're in today, what is the benefit that you see doing a stock buyback? Why not keep the cash on the balance sheet to allow greater flexibility if there's any deals that come up opportunistically in the future?
    Vincent J. Milano - Chairman, Chief Executive Officer and President

    So Phil, we appreciate the provocative statement about how we'll be valued and it's a thought that we actually consider. So your point is a good one. I think if you look at it mathematically, you're right. The earnings power drives the technical rationale for why we buy back the stock, if you think it's undervalued. But again, we -- our business may be better than we expect and we may become a higher-growth earnings company sooner than we have targeted. So all we're really saying is that we're open to evaluate that continuously. And the fact that you raised it, it's certainly a factor in this space.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
49.960.00(0.00%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.